Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Nov 26;109(11):2792-7.
doi: 10.1038/bjc.2013.657. Epub 2013 Oct 24.

The effect of metformin on apoptosis in a breast cancer presurgical trial

M Cazzaniga  1 , A DeCensi, G Pruneri, M Puntoni, L Bottiglieri, C Varricchio, A Guerrieri-Gonzaga, O D Gentilini, G Pagani, P Dell'Orto, M Lazzeroni, D Serrano, G Viale, B Bonanni
Affiliations
Clinical Trial

The effect of metformin on apoptosis in a breast cancer presurgical trial

M Cazzaniga et al. Br J Cancer. .

Abstract

Background: Metformin has been associated with antitumour activity in breast cancer (BC) but its mechanism remains unclear. We determined whether metformin induced a modulation of apoptosis by terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) overall and by insulin resistance status in a presurgical trial.

Methods: Apoptosis was analysed in core biopsies and in surgical samples from 100 non-diabetic BC patients participating in a randomised trial of metformin vs placebo given for 4 weeks before surgery.

Results: Eighty-seven subjects (45 on metformin and 42 on placebo) were assessable for TUNEL measurement at both time points. TUNEL levels at surgery were higher than that at baseline core biopsy (P<0.0001), although no difference between arms was noted (metformin arm: median difference surgery-biopsy levels +4%, interquartile range (IQR): 2-12; placebo arm: +2%, IQR: 0-8, P=0.2). Ki67 labelling index and TUNEL levels were directly correlated both at baseline and surgery (Spearman's r=0.51, P<0.0001). In the 59 women without insulin resistance (HOMA index<2.8) ,there was a higher level of TUNEL at surgery on metformin vs placebo (median difference on metformin +4%, IQR: 2-14 vs +2%, IQR: 0-7 on placebo), whereas an opposite trend was found in the 28 women with insulin resistance (median difference on metformin +2%, IQR: 0-6, vs +5%, IQR: 0-15 on placebo, P-interaction=0.1).

Conclusion: Overall, we found no significant modulation of apoptosis by metformin, although there was a trend to a different effect according to insulin resistance status, with a pattern resembling Ki67 changes. Apoptosis was significantly higher in the surgical specimens compared with baseline biopsy and was directly correlated with Ki67. Our findings provide additional evidence for a dual effect of metformin on BC growth according to insulin resistance status.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Boxplots of TUNEL levels by allocated arm at baseline and surgery. No difference between arms was noted (P=0.2, adjusted for age, BMI, baseline TUNEL and Ki67 LI). Median TUNEL levels were significantly higher at surgery compared with baseline biopsy in both arms (P<0.0001).
Figure 2
Figure 2
Boxplots of TUNEL levels by allocated arm and HOMAi according to a cutoff level of 2.8. The interaction between treatment and HOMAi was borderline significant (P=0.1).
Figure 3
Figure 3
Correlation between Ki67 and TUNEL values at baseline in all study patients regardless of treatment arm (Spearman's r=0.5, P<0.0001).
Figure 4
Figure 4
Correlation between Ki67 and TUNEL values at surgery in all study patients regardless of treatment arm (Spearman's r=0.5, P<0.0001).
See this image and copyright information in PMC

References

    1. Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, Gennari A, Trabacca MS, Galimberti V, Veronesi P, Johansson H, Aristarco V, Bassi F, Luini A, Lazzeroni M, Varricchio C, Viale G, Bruzzi P, Decensi A. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol. 2012;30:2593–2600. - PubMed
    1. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998;47:1643–1649. - PubMed
    1. Bosco JL, Antonsen S, Sorensen HT, Pedersen L, Lash TL. Metformin and incident breast cancer among diabetic women: a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2011;20:101–111. - PubMed
    1. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diab Care. 2006;29:254–258. - PubMed
    1. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–591. - PubMed

Publication types

MeSH terms